GENE ONLINE|News &
Opinion
Blog

Heart Disease
Alnylam Pharma Shares Dip Despite Positive Phase 3 HELIOS-B Heart Disease Results
2024-09-04
‘Heart Attack on a Chip’ Sheds Light on Personalized Drugs Trials
2022-12-14
Bristol Myers Squibb’ sNDA for Rare Heart Disease Treatment Accepted by the FDA
2022-10-21
Potential Novel Anti-thrombotic Treatment by Ionis Pharmaceuticals
2022-07-28
Cytokinetics Poised to Begin Phase 3 after its HCM Drug Registers Encouraging Data
2021-07-21
Verve Makes Successful Wall Street Debut on Back of its Promising Base Editor
2021-06-20
With $41.9 Million from Oversubscribed Financing Round, XyloCor Sets Sights on Gene Therapy for Heart Disease
2021-03-23
Tenaya Raises $106 Million Series C Round To Fight Heart Disease
2021-03-04
Verve Raises $94M in Series B, Aims to Disrupt Cardiology Market with ‘Once-and-Done’ Gene Editing Therapies
2021-01-21
Why is Bristol Myers Squibb Investing $13.1 Billion in MyoKardia?
2020-10-06
Encouraging Performance of Cardiovascular Drug Vindicates Novartis’ $9.7 Billion Buyout Deal
2020-09-06
Verve Therapeutic’s One Time Base Editing Treatment Cuts Down Cholesterol Levels in Blood
2020-06-30
Weekly in Asia |Nov
2019-11-12
LATEST
AI-Powered Blood Test Achieves 98% Accuracy in Early Breast Cancer Detection
2024-12-11
Vice President Hsiao Bi-Khim Advocates Innovations in Medtech, Biotech, and Healthtech
2024-12-11
Six Game-Changing Cancer Treatments Built for Unstoppable Growth in 2025 – Part II
2024-12-11
Six Game-Changing Cancer Treatments Built for Unstoppable Growth in 2025 – Part I
2024-12-11
Healthcare Revolution: Leeuwenhoek Joins Hands with Key Companies and Experts at Healthcare+ Expo Taiwan 2024
2024-12-11
2024 Taiwan Healthcare+ Expo: Innovations in Five Key Industries
2024-12-11
Core8 Group and MedArmor to Pioneer Vietnam’s First AI x ESG Hospital
2024-12-10
EVENT
Scroll to Top